# Marrow Therapeutics Launches With $173 Million

> Marrow Therapeutics secures $173 million for bone marrow-targeted medicines to treat blood disorders.
- Title: Marrow Therapeutics Launches With $173 Million · Pulse 2.0
- Summary: Marrow Therapeutics secures $173 million for bone marrow-targeted medicines to treat blood disorders.
- Keywords: marrow therapeutics, series a funding, series b funding, sickle cell disease, beta thalassemia, transferrin receptor, genetic medicines, bone marrow disorders, Pulse 2.0
- URL: https://shortify.news/Pulse_2.0/marrow-therapeutics-launches-with-173-million
- Source: Pulse 2.0 — https://pulse2.com/marrow-therapeutics-launches-with-173-million-for-bone-marrow-targeted-medicines
- Author: Amit Chowdhry
- Published: 2026-11-17T16:22:25+00:00
- Read time: 1 min
- Topics: marrow therapeutics, series a funding, series b funding, sickle cell disease, beta thalassemia, transferrin receptor, genetic medicines, bone marrow disorders, startups, business
## Funding Announcement
Marrow Therapeutics has launched with $173 million in combined Series A and Series B funding to develop genetic medicines for severe blood and bone marrow disorders.
## Funding Breakdown
The $53 million Series A round was co-led by Scion Life Sciences and venBio, with OrbiMed leading a subsequent $120 million Series B financing.
## Investors
All Series A investors participated in the Series B alongside RTW Investments, Surveyor Capital, Opaleye, NEXTBio Capital, Affinity Advisors, KKR, Spruce Street Capital, and Columbia Threadneedle Investments.
## Company Background
Scion Life Sciences founded Marrow Therapeutics, which is headquartered in Watertown, Massachusetts.
## Bone Marrow-Targeting Platform
Marrow is developing engineered antibodies that target the transferrin receptor, also known as TfR1, in bone marrow.
## Platform Purpose
The company’s Transferrin Antibody Bioconjugate platform delivers therapeutic payloads directly to bone marrow cells for multiple hematologic and bone marrow diseases.
## Lead Program Targets Two Blood Disorders
Marrow’s lead candidate, MAR-101, is being developed for sickle cell disease and beta thalassemia through studies to support an investigational new drug application.
## Therapeutic Strategy
MAR-101 decreases BCL11A and reactivates fetal hemoglobin production to treat sickle cell disease and beta thalassemia.
## Pipeline in a Product
Marrow uses a single therapeutic approach for both conditions, calling it a 'pipeline in a product' strategy to validate the platform across multiple diseases.
## Key takeaway

Marrow Therapeutics received $173 million in funding to develop genetic medicines for severe blood and bone marrow disorders.

---

Summary: Shortify — https://shortify.news/Pulse_2.0/marrow-therapeutics-launches-with-173-million
Reporting: Pulse 2.0 — https://pulse2.com/marrow-therapeutics-launches-with-173-million-for-bone-marrow-targeted-medicines

When you use this summary, link the Shortify URL for the summary and credit the reporting to its newsroom.